{"product_id":"the-handbook-of-clinically-tested-herbal-remedies-volumes-1-2-9780415652469","title":"The Handbook of Clinically Tested Herbal Remedies","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eA single source for accurate scientific information on herbal remedies!\u003cbr\u003e\u003cbr\u003eThis comprehensive handbook (comprised of two volumes of 700+ pages each) provides a snapshot of 160 herbal products that have been tested in clinical trials. Details of the products and the clinical trials they underwent are here in an easy-to-read, at-a-glance format.  \u003cbr\u003e\u003cbr\u003eEach botanical profile in The Handbook of Clinically Tested Herbal Remedies contains a summary section (table, text and references), followed by product information and clinical trials for that particular product. An evaluation of the strength of the evidence from the trials, along with the context for therapeutics is included to give you a complete picture of each remedy and its usefulness or lack thereof. If there is more than one product based on a particular botanical then the trials are grouped according to the product.\u003cbr\u003e\u003cbr\u003eThis valuable book also makes purchasing easy with manufacturer contact information. With o\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eVOLUME 1\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e About the Editor\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Contributors\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Preface\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Acknowledgments\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Editor’s Note\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e PART I: FUNDAMENTALS OF HERBAL MEDICINE\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 1. History and Regulation of Botanicals in the United States (Loren D. Israelsen and Marilyn Barrett)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Introduction\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e History\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e DSHEA Explained\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Drugs: OTC and Rx\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Prospectus\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 2. Product Definition Deficiencies in Clinical Studies of Herbal Medicines (Varro E. Tyler)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 3. Identifying and Characterizing Botanical Products (Marilyn Barrett)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Identifying Plants by Name\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Means of Assuring Plant Identity\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Preparations and Formulations\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Dose\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Bioavailability\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Guidelines\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Appendix: Preparations and Formulations\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 4. Standardization of Botanical Preparations: What It Does and Does Not Tell Us (Uwe Koetter and Marilyn Barrett)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Introduction\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Standardization of Therapeutic Activity\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Standardization to Meet a Chemical Norm\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Standardization As a Reflection of Quality Assurance Programs\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Guidance\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Situation in the Marketplace\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Perspective\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 5. The Importance and Difficulty in Determining the Bioavailability of Herbal Preparations (Anton Biber and Friedrich Lang)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 6. Borrowed Science and Phytoequivalence: Can Two Herbal Products Be Judged Equivalent? (Marilyn Barrett)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chemical or Pharmaceutical Equivalency\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Bioequivalency or Therapeutic Equivalency\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Application of the Concepts, Ginkgo As an Example\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Meta-Analyses\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Perspective\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 7. Determining Efficacy of Herbal Preparations (Tieraona Low Dog)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Observational Medicine\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Evidence-Based Medicine\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Summary\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 8. Evaluating Safety of Herbal Preparations (Ezra Béjar, Joseph M. Betz, and Marilyn Barrett)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Evaluation of Safety\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Adverse Reactions\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Adverse-Event Reporting Systems \u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Categorization According to the Degree of Safety\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Product Quality As an Aspect of Safety\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Contraindications\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Drug-Herb Interactions\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Improving Our Knowledge of Safety\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 9. Conducting Clinical Trials on Herbal Dietary Supplements in North America: Commercialization, Confidence, and Conflicts (Anthony L. Almada)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e The Spirit to Sponsor: Is There an Adequate Economic Incentive to Fund Research?\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Extracting Value from Science\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Competitor Kevlar: Preventing Piracy of Product-Specific Data\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e How Much Data Is Enough?\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e We Have DataNow What?\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Who Has Science and How Did They Acquire It?\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Conclusion\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 10. Motives for Conducting Clinical Trials on Botanicals in Europe: A Focus on Germany (Joerg Gruenwald and Stefan Spiess)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e Chapter 11. Pharmacopoeias and Botanical Monographs (Marilyn Barrett, Roy Upton, and V. Srini Srinivasan)\u003cbr\u003e \u003c\/li\u003e\n\u003cli\u003e \u003ci\u003eUnited States Pharmacopeia and National Formulary (USP-NF)\u003c\/i\u003e \u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e American Herbal Pharmacopoeia (AHP) and Therapeutic Compendium\u003cbr\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e European Pharmacopoeia (EP)\u003cbr\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e British Herbal Pharmacopoeia (BHP) and British Herbal Compendium (BHC)\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003cbr\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e German Commission E\u003cbr\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e European Scientific Cooperative of Phytotherapy (ESCOP)\u003cbr\u003e \u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e \u003ci\u003e\u003ci\u003eChinese Pharmacopoeia\u003c\/i\u003e \u003c\/i\u003e\n\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e African Pharmacopoeia\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e The Pharmacopoeia of Japan\u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e The Pharmacopoeias of India\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e World Health Organization (WHO)\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e Other Pharmacopoeias\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e Summary and Perspective\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e Sources of Pharmacopoeias\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e PART II: METHODS\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e Chapter 12. Methods of Product and Trial Inclusion and Evaluation (Marilyn Barrett)\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ci\u003e\u003ci\u003e Gathering Information on Products and Trials\u003cbr\u003e \u003c\/i\u003e\u003c\/i\u003e\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Taylor \u0026 Francis Ltd","offers":[{"title":"Default Title","offer_id":51018177970519,"sku":"9780415652469","price":68.31,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780415652469.jpg?v=1750775910","url":"https:\/\/bookcurl.com\/products\/the-handbook-of-clinically-tested-herbal-remedies-volumes-1-2-9780415652469","provider":"Book Curl","version":"1.0","type":"link"}